The findings from Policy Cures Research’s Global funding for snakebite envenoming research 2007-2018 report, commissioned by the Wellcome Trust, were presented at the third Snakebites Funders Forum, hosted by the Wellcome Trust in London on 15 November 2019.
The findings explore the results of the first ever survey on global investment of snakebite research, which was conducted as part of this project. The project was based on the G-FINDER survey of neglected disease biomedical R&D, which was expanded to include snakebite-related operational, implementation and health systems and policy research, based on the areas of interest identified by the Wellcome Trust and a panel of independent international experts.
The survey collected 12 years of data (2007 to 2018), allowing for time-series analysis. This report provides an overview of the landscape of researchers active in snakebite envenoming research and explores trends across the 12-year period, highlighting areas of unmet need.
Snakebite envenoming was also included in the G-FINDER survey for neglected diseases for the first time in 2019. Investment in biomedical R&D for snakebite envenoming will continue to be tracked by G-FINDER in future years.
For further information on snakebite envenoming R&D funding please contact Juliette Borri: email@example.com
‘Research for implementation’ – implementation research, operational research, and health systems research – plays a critical role in both shaping the development of new health technologies so that they are designed for the conditions in which they are used, and ensuring that they are introduced in the right place, at the right time, and in the right quantities. But with no established investment-tracking effort in this area of research, a lack of consensus around definitions, and limited capacity to identify and track this funding at the institutional, national, and subnational levels, understanding the global funding landscape of research for implementation is a major challenge.
Policy Cures Research, together with the Foundation for Innovative New Diagnostics, Innovative Vector Control Consortium, Medicines for Malaria Venture, and WHO’s Global Malaria Programme, has contributed to a new report developed by Malaria No More UK, PATH and TDR, which looks at global funding for malaria research and development (R&D) over the last decade, and highlights gaps in financial reporting and monitoring tools to document funding for malaria research for implementation. Excerpts of the new report, Investigating a Second Valley of Death in Malaria R&D: How is research for implementation funded?, are now available, with the full report to be published in June 2018.
The Return on innovation: A smart investment for the US report, written by Policy Cures Research (PCR) with the Global Health Technologies Coalition (GHTC) was launched in Washington DC in July 2017, examining the return on investment for the United States in supporting global health R&D.
The report explores the investments made and the role played by key US institutions such as USAID, the NIH, DoD and CDC. It explores the achievements that have already been made with the help of US investments, as well as how this investment has contributed to a pipeline of products to address global health needs. The report finds that US government investment of around $14 billion in R&D for global health has been a smart investment, featuring several successful case-studies of US research investments to address diseases such as HIV/AIDS, TB, Ebola and meningitis. For example, US government support of the Meningitis Vaccine Project was instrumental in the development of MenAfriVac – the first ever conjugate vaccine against meningitis A, available at a price of just 50 cents a dose.
It notes that despite these successes, there is still a critical underinvestment globally in R&D to deliver urgently-needed drugs, vaccines, diagnostics and other tools for neglected diseases and health conditions – with investment in R&D for global health representing only around 1-2% of spending on health R&D each year. The report concludes that the US government’s role in global health R&D is vital, and the benefits are clear. It finds that the US government investment plays an essential and catalytic role in developing new drugs, vaccines, diagnostics and other urgently-needed tools for neglected disease, delivering economic and security returns for Americans.
The European public sector plays a pivotal role in supporting research and development (R&D) to deliver new tools to combat poverty-related and neglected diseases (PRNDs). PRNDs include diseases such as leprosy, diarrhoeal diseases, dengue, helminth infections and trachoma. In an era in which global public funding for neglected disease R&D is waning, and governments face competing demands for health and R&D budgets, this report provides a timely reminder of why the European contribution matters.
This report analyses how European Union funding for PRND R&D compares with the direct investments made by European governments. It assesses the impact that this investment has had on global health and the economic and employment benefits it has created for Europe.
Commissioned by Deutsche Stiftung Weltbevölkerung (DSW), the Saving Lives report updates a previous 2012 study. The Saving Lives report was formally launched in November 2016 at the eighth EDCTP Forum in Lusaka, Zambia.
The G-FINDER project collates comprehensive primary data from a tailored survey with a scope that has been refined by an expert advisory committee and staff at Policy Cures Research. Each year, a comprehensive report is published which includes the latest data on funding for neglected disease R&D from the previous financial year.
R&D Product Pipeline
Policy Cures Research maintains an online R&D pipeline database for neglected diseases.
- Access the latest pipeline pages